Citigroup
LUMO

Citigroup’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Citigroup’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,067
Closed -$44K – 7866
2018
Q3 		$44K Sell
2,067
-1,177
-36% -$35.8K ﹤0.01% 6634
2018
Q2 		$139K Buy
3,244
+2,711
+509% +$124K ﹤0.01% 5410
2018
Q1 		$35K Sell
533
-545
-51% -$38.6K ﹤0.01% 6416
2017
Q4 		$79K Sell
1,078
-444
-29% -$36.7K ﹤0.01% 5847
2017
Q3 		$139K Buy
1,522
+411
+37% +$31.5K ﹤0.01% 5295
2017
Q2 		$74K Sell
1,111
-122
-10% -$15.1K ﹤0.01% 5551
2017
Q1 		$268K Sell
1,233
-2,000
-62% -$286K ﹤0.01% 4414
2016
Q4 		$299K Sell
3,233
-656
-17% -$73.9K ﹤0.01% 4934
2016
Q3 		$526K Sell
3,889
-433
-10% -$43K ﹤0.01% 3856
2016
Q2 		$438K Sell
4,322
-1,389
-24% -$172K ﹤0.01% 3809
2016
Q1 		$935K Buy
5,711
+1,544
+37% +$313K ﹤0.01% 3419
2015
Q4 		$1.36M Buy
4,167
+145
+4% +$47.2K ﹤0.01% 2808
2015
Q3 		$1.3M Sell
4,022
-1,356
-25% -$596K ﹤0.01% 2833
2015
Q2 		$2.14M Buy
5,378
+4,467
+490% +$1.9M ﹤0.01% 2453
2015
Q1 		$449K Buy
+911
New +$353K ﹤0.01% 3845

Other funds holding LUMO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's LUMO Position: Q2 2021 in Review

Citigroup sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2021, closing a stake of 1,000 shares — an estimated $12K sold.

Citigroup first reported a position in LUMO in Q2 2013 and held it in 27 quarters. The position peaked at $958K in Q1 2016. 40 funds tracked by Wall St. Rank hold LUMO as of Q2 2021.

  • Citigroup reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Citigroup sold 1,000 Lumos Pharma, Inc. Common Stock shares in Q2 2021, an estimated $12K.
  • Citigroup first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Citigroup's Lumos Pharma, Inc. Common Stock position peaked at $958K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.